Skip to main content

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Hypogammaglobulinaemia risk increased with rituximab in MS

Susanna Hallberg highlights hypogammaglobulinaemia as an important side effect of long-term rituximab treatment in MS, and makes recommendations on how to manage it in patients (2:32).

Funding for independent interviews at ECTRIMS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.